We are live on
!
Find out more
LCP
Lamond Capital Partners Portfolio holdings
AUM
$14.3M
1-Year Est. Return
30.74%
This Fund
S&P 500
This Quarter
Est. Return
-3.58%
1 Year Est. Return
-30.74%
3 Year Est. Return
+54.28%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$14.3M
AUM Growth
-$52.6M
(-79%)
Cap. Flow
-$51.9M
Cap. Flow
% of AUM
-363.65%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
6
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$18.3M |
| 2 |
Puma Biotechnology
PBYI
|
+$17.3M |
| 3 |
Amgen
AMGN
|
+$12.2M |
| 4 |
AbbVie
ABBV
|
+$2.79M |
| 5 |
RXDX
Ignyta, Inc.
RXDX
|
+$626K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Technology | 0% |
No holdings matched the selected filter criteria.
Similar funds
HCM
PPF
PM
TSU
RCMC
SCA
GFWEV
STA
Lamond Capital Partners's Q1 2016 Portfolio in Review
As of Q1 2016, Lamond Capital Partners held 7 positions worth $14.3M, down 79% from $66.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Lamond Capital Partners withdrew a net $51.9M in Q1 2016, closing 6 positions and reducing 1 holding. Its most notable exit was Oracle, an estimated $18.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 72% a quarter earlier, followed by Technology.
- Lamond Capital Partners's biggest Q1 2016 reduction was AbbVie, cutting an estimated $2.79M.
- Lamond Capital Partners fully exited Oracle in Q1 2016, selling an estimated $18.3M.
- Lamond Capital Partners's ten largest holdings make up 100% of its $14.3M portfolio in Q1 2016.
- Lamond Capital Partners opened 0 new positions and closed 6 in Q1 2016.
- Lamond Capital Partners's portfolio value fell 79% quarter-over-quarter to $14.3M.
Based on Lamond Capital Partners's 13F filing for Q1 2016, filed 5 May 2016.